IDERA PHARMACEUTICALS, INC. Separation Agreements
6 Contracts & Agreements
- Executive Separation Agreement, dated as of August 15, 2023, entered into by and between Aceragen, Inc. and John Taylor (Filed With SEC on August 16, 2023)
- Amendment No. 1 to Executive Transition and Separation Agreement, by and among Daniel Soland and Aceragen, Inc., dated February 10, 2023 (Filed With SEC on April 13, 2023)
- Amendment No. 1 to Executive Transition and Separation Agreement, by and among Vincent Milano and Aceragen, Inc., dated February 10, 2023 (Filed With SEC on April 13, 2023)
- Executive Transition and Separation Agreement by and among Daniel Soland and Idera Pharmaceuticals, Inc., dated September 28, 2022 (Filed With SEC on September 30, 2022)
- Executive Transition and Separation Agreement by and among Vincent Milano and Idera Pharmaceuticals, Inc., dated September 28, 2022 (Filed With SEC on September 30, 2022)
- SEPARATION AGREEMENT AND RELEASE OF CLAIMS (Filed With SEC on August 7, 2017)
